EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Do-it-yourself game plans

Stage 3: Who should you contact, and what should you request?

Dose Diligence research deskSection 02 · Page 5 of 17Last updated 17 Nov 2026

Contact the people who own the evidence and workflow, not only the sales representative. Start with a small, relevant candidate set and send each candidate the same request for information, or RFI.

Which contacts are useful?

ContactPurposeStarting point
Manufacturer-linked provider supportConfirm current product routing, programme terms and patient workflowLillyDirect HCP page; NovoCare HCP page
Wholesaler new-account or pharmaceutical-distribution teamDetermine account eligibility and whether the exact product can be quotedFor example, McKesson pharmaceutical distribution; inclusion is not confirmation of GLP-1 access
Pharmacy owner or pharmacist-in-chargeConfirm legal entity, dispensing locations, products and escalation responsibilitiesRequest a direct introduction from the proposed counterparty
Pharmacy quality/compliance leadObtain inspection responses, corrective-action evidence, provenance and recall proceduresRequire facility-specific documents
Home-state and destination-state pharmacy boardsIndependently check licences and clarify unresolved licence scopeFor example, Texas verification
US pharmacy/telehealth counselReview route eligibility, remuneration, state requirements and contractsSelect counsel with relevant product and operating-model experience
Integration and security ownerTest status visibility, data flows and failure handlingRequire participation before contract execution

For operational reference, Lilly's reviewed provider page lists 855-723-4672, NPI 1912889320 and NCPDP 1574056. NovoCare's reviewed provider page lists 1-866-898-9368, NPI 1225959968 and NCPDP 1311961. Reconfirm these identifiers against the live manufacturer instructions before configuring your EHR. LillyDirect; NovoCare.

What should your supplier RFI ask for?

Request the following in a structured response, with supporting files:

  1. Entity map: contracting entity, operating names, ownership and every proposed dispensing or production location.
  2. Product schedule: exact approved product/presentation or proposed compounded preparation; package size; concentration where relevant; product identifiers.
  3. State schedule: licence numbers, types, expiry dates and products accepted in each destination state.
  4. Legal explanation: the basis asserted for any compounded preparation and intended arrangement.
  5. Quality file: relevant inspections, observations, responses, corrective actions, recalls and complaint-handling procedures.
  6. Provenance: authorised sourcing evidence for approved products; appropriate ingredient and finished-preparation evidence for any conditionally assessed compounded product.
  7. Capacity: present throughput, available incremental capacity, peak limits and allocation rules for the requested products and states.
  8. Service data: recent fulfilment performance with definitions, denominators and exclusions—not only an average shipping claim.
  9. Commercial schedule: all prices, fees, eligibility conditions, minimums, deposits, credits, cancellation rules and quote validity.
  10. Patient journey: prescribing, clarification, payment, authorisation, dispatch, tracking, counselling and refill responsibilities.
  11. Technology and privacy: integrations, subcontractors, data fields, security evidence and proposed agreements.
  12. Exit plan: outstanding orders, transfers, data export, unspent balances and transition assistance.

Ask candidates to mark each response documented fact, supplier assertion, not available, or not applicable with explanation.

What should the first email say?

We are assessing a GLP-1 dispensing/access arrangement for a US provider network operating in [states]. We expect [aggregate volume] prescriptions by [product/presentation] and are considering [patient dispensing / facilitated access / clinic stock]. Please identify the exact contracting and fulfilling entities and return the attached RFI. We are not requesting patient data, a treatment protocol or a general assurance that your business is compliant. Product-specific eligibility, quality, operational capability and commercial terms will be reviewed separately.

Stage 3 exit document: a candidate register with completed responses, unresolved questions and explicit exclusion reasons.

Explore the table row by row

A working view of the research

Manufacturer-linked provider support

Purpose
Confirm current product routing, programme terms and patient workflow

Answers stay in this session unless you choose to save. No account needed.

Sources cited on this page

  1. lilly.com · Source 1 ↗https://www.lilly.com/lillydirect/hcp/
  2. novocare.com · Source 2 ↗https://www.novocare.com/hcp/delivery.html
  3. mckesson.com · Source 3 ↗https://www.mckesson.com/pharmaceutical-distribution/pharmaceutical-products/
  4. pharmacy.texas.gov · Source 4 ↗https://www.pharmacy.texas.gov/DBSEARCH/default.asp
Section sources →